GoodRx (GDRX) Projected to Post Earnings on Wednesday

GoodRx (NASDAQ:GDRX) is expected to be posting its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect GoodRx to post earnings of $0.09 per share and revenue of $193.2670 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

GoodRx Stock Up 1.8%

Shares of GoodRx stock opened at $2.22 on Wednesday. GoodRx has a twelve month low of $2.10 and a twelve month high of $5.81. The stock has a market cap of $753.53 million, a price-to-earnings ratio of 24.67, a price-to-earnings-growth ratio of 0.83 and a beta of 1.50. The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 0.81. The company has a fifty day moving average price of $2.59 and a 200 day moving average price of $3.35.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on GDRX shares. TD Cowen lowered their target price on GoodRx from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Monday, November 10th. Morgan Stanley lowered their price objective on shares of GoodRx from $5.00 to $4.00 and set an “equal weight” rating for the company in a research report on Thursday, December 18th. UBS Group reduced their target price on shares of GoodRx from $4.25 to $4.00 and set a “neutral” rating on the stock in a research report on Thursday, November 6th. JPMorgan Chase & Co. decreased their target price on shares of GoodRx from $6.00 to $5.00 and set an “overweight” rating for the company in a research note on Tuesday, November 11th. Finally, Citigroup dropped their price target on shares of GoodRx from $5.00 to $4.50 and set a “buy” rating on the stock in a research note on Friday, January 9th. Five research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, GoodRx has a consensus rating of “Hold” and a consensus target price of $4.73.

Institutional Trading of GoodRx

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in GoodRx by 7.3% during the 3rd quarter. Vanguard Group Inc. now owns 9,207,340 shares of the company’s stock worth $38,947,000 after buying an additional 624,182 shares during the last quarter. Ameriprise Financial Inc. raised its position in shares of GoodRx by 4.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 4,819,505 shares of the company’s stock valued at $24,001,000 after acquiring an additional 184,734 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in GoodRx by 6.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,650,452 shares of the company’s stock worth $7,183,000 after purchasing an additional 152,934 shares during the last quarter. AQR Capital Management LLC lifted its stake in GoodRx by 188.0% during the fourth quarter. AQR Capital Management LLC now owns 1,158,546 shares of the company’s stock worth $3,140,000 after purchasing an additional 756,209 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in GoodRx by 22.1% in the fourth quarter. Geode Capital Management LLC now owns 1,135,563 shares of the company’s stock worth $3,078,000 after purchasing an additional 205,628 shares during the period. 63.77% of the stock is owned by institutional investors.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.